Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 7, 2006; 12(33): 5272-5280
Published online Sep 7, 2006. doi: 10.3748/wjg.v12.i33.5272
Published online Sep 7, 2006. doi: 10.3748/wjg.v12.i33.5272
Table 2 Indications for screening with anti-HCV antibody
Risk factors for which testing is indicated by all the guidelines | Risk factors for which testing is indicated by some of the guidelines | Additional risk factors for which testing is not formally recommended |
Intravenous drug use (past and present) | Populations with high HCV prevalence[12,30] | Injections with reusable glass syringes[32] |
Blood transfusion or transplantation before 1992 (or by known HCV positive donor) | Incarceration[12,33] | Heavy marijuana use[34] |
Administration of clotting factors before 1997 | Hepatitis B virus infection[12,33] | Promiscuous sex[34] |
Clinical or biochemical evidence for chronic liver disease | Sharing intranasal cocaine equipment[12,33] | Poverty[34,35] |
Percutaneous exposures to HCV | History of sexually transmitted disease[12,33] with genital erosions[28] | History of invasive procedures[36] |
Haemophilia | Traumatic sex or vaginal sex during menstruation[14,33] | History of surgery[36] |
Children born to HCV + ve mothers | Health Care Workers performing procedures at risk of transmission to the patient[37] | Beauty treatments[38] |
HIV positivity | ||
Stable sexual partners of HCV + patients |
- Citation: Poggio PD, Mazzoleni M. Screening in liver disease. World J Gastroenterol 2006; 12(33): 5272-5280
- URL: https://www.wjgnet.com/1007-9327/full/v12/i33/5272.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i33.5272